Illumina, Inc. vs JPMorgan Ultra Short Income ETF — how do they compare? Illumina, Inc. trades at $193.06 (market cap $29.12B), while JPMorgan Ultra Short Income ETF trades at $50.45. The key difference: Illumina, Inc. is trading nearer its 52-week high, JPMorgan Ultra Short Income ETF nearer its low. Which is the better fit depends on your goals.
| ILMN | JPST | |
|---|---|---|
Market Cap | $29.12B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $205.10 | $50.78 |
52-Week Low | $91.00 | $50.40 |
Enterprise Value | $30.48B | — |
Trailing returns across standard periods
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.
Read more on JPST →